|
|
|
07.07.25 - 14:06
|
GE HealthCare to announce second quarter 2025 results on July 30, 2025 (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for m...
|
|
|
|
|
01.07.25 - 14:36
|
GE HealthCare announces cash dividend for second quarter of 2025 (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.06.25 - 10:48
|
Global Clinical Workflow Management Software Market Projected to Reach USD USD 40,243 million by 2030., Growing at a 22.97% CAGR: MarkNtel Advisors - Leading key players (GE Healthcare, Oracle Health, Allscripts Healthcare Solutions, Siemens Healthin (PR Newswire)
|
|
|
NEW DELHI, June 10, 2025 /PRNewswire/ -- The Global Clinical Workflow Management Software Market size is set to experience significant growth in the coming years. Valued at around USD 11,640 Million in 2024, it is expected to soar to nearly USD 40,243 Million by 2030, with a staggering......
|
|
|
28.05.25 - 20:57
|
Exo® Announces Samsung Medison Strategic Collaboration and Welcomes Omar Ishrak to its Board (Business Wire)
|
|
|
Exo set to accelerate its game-changing ultrasound technology developmentSANTA CLARA, Calif.--(BUSINESS WIRE)--#Innovation--Exo Imaging, a leading innovator in ultrasound medical imaging technology, today announced a strategic collaboration with Samsung Medison to co-develop advanced ultrasound solutions. The partnership includes a strategic equity investment by Samsung, aimed at accelerating the development of next-generation ultrasound platforms. Exo is also delighted to welcome Omar Ishrak to its Board as Chair of Strategy.
Dr. Kyu Tae Yoo, CEO of Samsung Medison, welcomed the partnership with Exo. “Our collaboration with Exo marks a significant step toward advancing transformation in ultrasound imaging. We are committed to delivering innovation that improves diagnostic capabilities and enhances the clinical experience for patients and practitioners alike.”
Omar Ishrak— Chairman of Qubit Health Capital, former Chairman and CEO of Medtronic, and prior CEO of GE Healthcare Systems said, “Exo's t...
|
|
|
22.05.25 - 13:01
|
MAGic™ BioProcessing appoints Jonathan Royce to Board of Directors (Cision)
|
|
|
Uppsala, Sweden – May 22, 2025 – MAGic BioProcessing (Lab-on-a-Bead AB) is pleased to announce the appointment of Jonathan Royce to its Board of Directors.
Jonathan is a seasoned C-suite leader with over 25 years of leadership experience in the life sciences sector, with a strong track record spanning industrial biotechnology, development, production, and commercial strategy. He has lead teams at organizations such as Millipore, GE Healthcare, Vironova, and Bio-Works Technologies, where he consistently drove innovation and growth across complex technical and commercial landscapes....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
